MARKET

GENB

GENB

Generate Biomedicines
NASDAQ
13.57
-0.23
-1.67%
Pre Market: 13.44 -0.13 -0.96% 08:03 10/08 EDT
OPEN
13.59
PREV CLOSE
13.80
HIGH
13.99
LOW
13.35
VOLUME
1.44K
TURNOVER
--
52 WEEK HIGH
22.67
52 WEEK LOW
11.00
MARKET CAP
1.74B
P/E (TTM)
-8.5287
1D
5D
1M
3M
1Y
5Y
1D
Generate Biomedicines Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
Generate Biomedicines: Buy Rating Reiterated as Platform and Pipeline Progress Support Unchanged $30 Price Target
TipRanks · 3d ago
HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target
Benzinga · 3d ago
Weekly Report: what happened at GENB last week (0928-1002)?
Weekly Report · 3d ago
Seven new option listings on October 2nd
TipRanks · 5d ago
Analysts Are Bullish on Top NA Stocks: Generate Biomedicines, Inc. (GENB), Netskope, Inc. (NTSK)
TipRanks · 6d ago
Generate Biomedicines, Roswell Park dose first patient in GB-5267 trial
TipRanks · 10/01 11:20
Roswell Park And Generate Biomedicines Announce First Patient Dosed In First-In-Human Clinical Trial Evaluating GB-5267, Investigational, Autologous IL-18 Armored CAR T-Cell Therapy
Benzinga · 10/01 11:14
More
About GENB
Generate Biomedicines, Inc. is a clinical-stage generative biology company focusing on the Artificial intelligence (AI) revolution in biotechnology and drug design and development. The Company is engaged in the field of generative biology using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its Generate Platform integrates generative and predictive models that learn design principles from proprietary data and graph neural networks, among other architectures. Its lead product candidate, GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma. Its other product candidates include GB-4362, a systemically administered monoclonal antibody designed to neutralize free monomethyl auristatin E (MMAE) as an adjunctive therapy to antibody-drug conjugate (ADC) molecules with an MMAE payload, as well as GB-5267, an armored, MUC16-directed CAR-T cell therapy candidate.

Webull offers Generate Biomedicines Inc stock information, including NASDAQ: GENB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GENB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GENB stock methods without spending real money on the virtual paper trading platform.